GlassScriptPhysician profile
Eyad Alhaj
NPI 1770698375
$4,635.74
in general payments reported to CMS, 2019-2025
32 companies · $582 in 2025
The $582 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,364 · 2020: $588 · 2021: $262 · 2022: $285 · 2023: $1,035 · 2024: $521 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873 · Travel and Lodging: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.71 |
| Travel and Lodging | $264.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $909.14 | 2019-2020 | |
| Medtronic, INC. | $804.09 | 2021-2024 | Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan, Micra |
| Boston Scientific Corporation | $727.08 | 2023-2025 | Watchman Access System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $342.73 | 2019-2024 | Ensite |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $251.72 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.49 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $158.65 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $149.99 | 2024 | Sapien 3 Ultra Resilia |
| Astellas Pharma US INC | $115.64 | 2020 | |
| Merck Sharp & Dohme LLC | $90.93 | 2024-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $88.96 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $84.70 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $80.39 | 2019-2025 | |
| Biosense Webster, INC. | $72.96 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $53.02 | 2024-2025 | Assure Wcd |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $50.54 | 2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $49.68 | 2019-2025 | Uptravi, Opsynvi, Opsumit |
| Amgen INC. | $49.42 | 2019-2020 | |
| Medical Device Business Services, INC. | $48.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $35.80 | 2019-2020 | |
| Abiomed | $33.09 | 2022 | |
| Cardiva Medical, INC. | $29.68 | 2024 | Cardiva Vascade 6/7f Vcs |
| Cordis US Corp. | $27.85 | 2025 | Mynx Control Venous |
| Pfizer INC. | $26.79 | 2019 | |
| Philips North America LLC | $24.77 | 2020 | |
| Inspire Medical Systems, INC. | $23.17 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $22.22 | 2025 | Amvuttra |
| Terumo Medical Corporation | $21.91 | 2019 | |
| Cardiovascular Systems INC. | $14.50 | 2019 | |
| Amarin Pharma, INC. | $14.49 | 2019 | |
| Biotronik INC. | $14.37 | 2019 | |
| Impulse Dynamics (USA) INC. | $13.99 | 2023 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eyad Alhaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.